Poster 1, poster 2 and interview. Two posters from the ABCD nationwide audit programme were presented at the EASD in Berlin between 2nd and 5th October 2018. Dr Amar Puttanna presented data from the canagliflozin audit looking at the impact of the canagliflozin on the first return to clinic after its commencement and then second return. A notable finding was that HbA1c, weight, alanine amino transferase and systolic blood pressure all continued to fall by significant amounts between the first return to clinic and the second return to clinic such that by the time of the second return to clinic the mean HbA1c had fallen from 76.3 to 65.3 mmol/mol and it was noteworthy that by the time of the second return to clinic at 55 weeks the weight had fallen by a mean of 4 kg from 101 to 97 kg. The poster can be viewed here.
Dr Chris Walton presented data from the liraglutide audit, using the UKPDS risk engine to assess cardiovascular risk in patients receiving liraglutide in routine clinical practice. Whilst we know from the LEADER study that in patients with high cardiovascular risk there is an impact on vascular outcomes, this was an attempt to gain insight into the potential benefit on ordinary patients in the clinic. The findings were that between three and nine months after starting liraglutide, there were highly significant falls in all parameters involved in CVD risk assessment other than HDL cholesterol which was unchanged. Overall the data suggested that the use of the liraglutide in 100 patients could prevent three events of coronary heart disease or stroke and save two or more lives over the next 10 years. The poster can be viewed here and there is also an interview with Dr Walton made by the EASD which can be viewed here.
